329 related articles for article (PubMed ID: 24402559)
41. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
42. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Cho JR; Rollini F; Franchi F; Ferrante E; Angiolillo DJ
Vasc Health Risk Manag; 2014; 10():177-88. PubMed ID: 24729713
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Kosoglou T; Reyderman L; Tiessen RG; van Vliet AA; Fales RR; Keller R; Yang B; Cutler DL
Eur J Clin Pharmacol; 2012 Mar; 68(3):249-58. PubMed ID: 21935705
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
[TBL] [Abstract][Full Text] [Related]
45. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
[TBL] [Abstract][Full Text] [Related]
46. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
48. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
Franchi F; Rollini F; Kairouz V; Rivas Rios J; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Been L; Piraino J; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Jennings LK; Bass TA; Angiolillo DJ
JACC Basic Transl Sci; 2019 Nov; 4(7):763-775. PubMed ID: 31998847
[TBL] [Abstract][Full Text] [Related]
50. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
51. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
52. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Frere C; Cuisset T; Quilici J; Camoin L; Carvajal J; Morange PE; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Oct; 98(4):838-43. PubMed ID: 17938809
[TBL] [Abstract][Full Text] [Related]
53. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
[TBL] [Abstract][Full Text] [Related]
54. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Serebruany VL; Fortmann SD; Rao SV; Tanguay JF; Lordkipanidze M; Hanley DF; Can M; Kim MH; Marciniak TA
Thromb Haemost; 2016 May; 115(5):905-10. PubMed ID: 26887783
[TBL] [Abstract][Full Text] [Related]
55. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
56. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Xiao Z; Théroux P
J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
[TBL] [Abstract][Full Text] [Related]
57. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Friebel J; Moritz E; Witkowski M; Jakobs K; Strässler E; Dörner A; Steffens D; Puccini M; Lammel S; Glauben R; Nowak F; Kränkel N; Haghikia A; Moos V; Schutheiss HP; Felix SB; Landmesser U; Rauch BH; Rauch U
Cells; 2021 Dec; 10(12):. PubMed ID: 34944024
[TBL] [Abstract][Full Text] [Related]
58. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
59. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Lu D; Owens J; Kreutz RP
Thromb Res; 2013 Aug; 132(2):e94-8. PubMed ID: 23920429
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
